Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration

2016180 citationsJournal Articlehybrid Open Access

Authors

Frank G. Holz · University of Bonn

Pravin U. Dugel · Southern California Eye Institute

Georges Weissgerber · Alcon (United States)

Robin Hamilton · University College London

Rufino Silva · University of Coimbra

Francesco Bandello · Vita-Salute San Raffaele University

Michael Larsen

Abstract

This first-in-human study of RTH258 demonstrated noninferiority in the change in CSFT at 1 month for the 4.5- and 6.0-mg doses compared with ranibizumab and an increase of 30 days in the median time to PBT for the 6.0-mg dose. There were no unexpected safety concerns, and the results support the continued development of RTH258 for the treatment of neovascular AMD.

Topics & Keywords

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal Development and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Ophthalmology

Volume 123, Issue 5, pp. 1080-1089

DOI: 10.1016/j.ophtha.2015.12.030

Field-Weighted Citation Impact: 6.08

Command Palette